Prostate-specific antigen-based screening for prostate cancer: Evidence, controversies and future perspectives

International Journal of Urology

Volumn 16, Issue 5, 2009, Pages 458-464

  Ito, Kazuto ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; HUMAN; JAPAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RELATIVE; REVIEW; UNITED STATES;

EVIDENCE-BASED MEDICINE; HUMANS; MALE; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 65549151645     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02293.x     Document Type: Review

References (48)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008 58 : 71 96.
2. Medicare. The Official U.S. Government Site for People with Medicare. Preventive Services. Prostate Cancer Screening (PSA) Cited 11 Nov 2008.] Available from URL: http://www.medicare.gov/health/prostate.asp
3. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003 289 : 1414 20. (Pubitemid 37430309)
4. Parkin DM, Whelan SL, Ferlar J et al. Cancer incidence in five continents Vol. I to VIII: international comparison of age-standardized incidence rates for prostate cancer in selected registries, males, 1993-1996. IARC CancerBase No. 7, Lyon, 2005.
5. Ito K, Raaijmakers R, Roobol M et al. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 2005 103 : 242 50. (Pubitemid 40129282)
6. Vital statistics in 2007 (Statistics and Information Department Minister's Secretariat Ministry of Health, Labour and Welfare, Japan): The number of mortality and mortality rate stratified by sex and cause of death (in Japanese). [Cited 14 Oct 2008.] Available from URL: http://www.mhlw.go.jp/ toukei/saikin/hw/jinkou/kakutei07/hyo7.html
7. Kuroishi T, Hirose K, Tominaga Y, Aoki K, Tajima K. Prediction of the future mortality of cancer in Japan. In : Oshima A, Kuroishi T, Tajima K (eds). White Paper on Cancer and Statistics- Incidence/Mortality/ Prognosis-2004. Shinohara-shuppan, Tokyo, 2004 219 34 (in Japanese).
8. Shaw PA, Etzioni R, Zeliadt SB et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am. J. Epidemiol. 2004 160 : 1059 69. (Pubitemid 39557458)
9. Siddequi SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J. Urol. 2008 179 : 1830 7.
10. Messing EM, Manola J, Yao J et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006 7 : 472 9. (Pubitemid 43779173)
11. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council Trial. Br. J. Urol. 1997 79 : 235 46.
12. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005 12 : 46 61. (Pubitemid 40333002)
13. Ito K, Kakehi Y and the Japanese Urological Association. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int. J. Urol. 2008 15 : 763 8.
14. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J. Clin. 2006 56 : 11 25. (Pubitemid 43228384)
15. American Urological Association (AUA). Prostate-Specific Antigen (PSA) best practice policy. Oncology (Huntingt) 2000 14 : 267 272, 277 278, 280 passim.
16. Suzuki H, Flanigan RC, Okuyama A. Prostate specific antigen (PSA)-based screening. Int. J. Urol. 2008 15 : 757 62.
17. US Preventive Services Task Force (USPSTF). Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 2008 149 : 185 92.
18. Aus G, Bergdahl S, Lodding P et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur. Urol. 2007 51 : 659 64. (Pubitemid 46110933)
19. Bartsch G, Horninger W, Klocker H et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008 101 : 809 16.
20. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999 38 : 83 91. (Pubitemid 29052946)
21. Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004 59 : 311 18. (Pubitemid 38509764)
22. Ciatto S, Gervasi G, Gorini G et al. Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993. Eur. J. Cancer 2006 42 : 1858 62. (Pubitemid 44149094)
23. Jemal A, Ward E, Wu X et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol. Biomarkers Prev. 2005 14 : 590 5. (Pubitemid 40500456)
24. Colloi JL, Amling CL. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America. Prostate Cancer Prostatic Dis. 2008 11 : 247 51.
25. Kubota Y, Ito K, Imai Y et al. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002 50 : 262 9. (Pubitemid 34184666)
26. Ito K, Yamamoto T, Miyakubo M et al. Lead time of prostate cancer detected in population-based screening for prostate cancer in Japan. J. Urol. 2007 178 : 1258 64. (Pubitemid 47368404)
27. Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O, Miki T. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int. J. Urol. 2008 15 : 156 60.
28. Lu-Yao G, Albertsen PC, Stanford JL et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002 325 : 740 5. (Pubitemid 35193190)
29. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J. Gen. Intern. Med. 2008 11 : 1809 14.
30. Concato J, Wells CK, Horwitz RI et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch. Intern. Med. 2006 166 : 38 43. (Pubitemid 43063839)
31. Perron L, Moore L, Bairati I et al. PSA screening and prostate cancer mortality. CMAJ 2001 166 : 586 91.
32. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003 168 : 31 5. (Pubitemid 36241178)
33. La Rosa F, Stracci F, Minelli L et al. Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects. Urology 2003 62 : 1040 4. (Pubitemid 37510087)
34. Threfall TJ, English DR, Rouse IL. Prostate cancer in West Australia: trends in incidence and mortality from 1985 to 1996. Med. J. Aust. 1998 169 : 21 4. (Pubitemid 28330454)
35. Skarsgard D, Tonia J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control. 2000 11 : 79 88.
36. Majeed A, Babb P, Jones J et al. Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int. 2000 85 : 1058 62. (Pubitemid 30348798)
37. Post PN, Kil PJ, Crommelin MA et al. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands, 1971-1995. Eur. J. Cancer 1998 34 : 705 9. (Pubitemid 28218948)
38. Brewster DH, Fraser LA, Harris V et al. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int. 2000 85 : 463 73. (Pubitemid 30142623)
39. Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials. 2000 21 (6 Suppl 273S 309S.
40. Andriole GL, Levin DL, Crawford ED et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J. Natl. Cancer Inst. 2005 97 : 433 8. (Pubitemid 40528606)
41. Schröder FH, Denis LJ, Roobol M et al. The story of the European Randomized Study of Screening for Prostate Cancer BJU Int. 2003 92 (Suppl 2 1 13. (Pubitemid 38091131)
42. Schröder FH, Roobol MJ, Damhuis RA et al. Rotterdam randomized pilot studies of screening for prostate cancer - an overview after 10 years. J. Natl. Cancer Inst. 2005 97 : 696. (Pubitemid 40812634)
43. Otto SJ, van der Cruijsen IW, Liem MK et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Int. J. Cancer 2003 105 : 394 9. (Pubitemid 36570054)
44. Roemeling S, Roobol MJ, Otto SJ et al. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial. Prostate 2007 67 : 1053 60. (Pubitemid 46983335)
45. Homma Y, Araki I, Igawa Y et al eds). Clinical Guideline for Male Lower Tract Symptoms. The Neurogenic Bladder Society. Backwell Publishing, Tokyo, 2008 (in Japanese).
46. Roemeling S, Roobol MJ, Postma R et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur. Urol. 2006 50 : 475 82. (Pubitemid 44189069)
47. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7. (Pubitemid 41124176)
48. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 2004 351 : 125 35. (Pubitemid 38886647)